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1INTRODUCTION
Transvaginal ultrasound is a non invasive diagnostic tool
commonly used to evaluate women with postmenopausal uterine
bleeding. The ultrasound examination for endometrial pathology
includes a measurement of endometrial thickness. In clinical studies,
endometrial malignancy is uncommon in women with an endometrial
thickness measurement less than 5 mm. This study specifically evaluates
transvaginal ultrasound measurements of endometrial thickness in
postmenopausal women. Because the endometrium contains estrogen
receptors and responds to circulating estrogens, endometrial thickness
constitutes a potential marker of estrogen status in postmenopausal
women. To the extent that transvaginal ultrasound effectively measures
the endometrial thickness and estrogen status, endometrial thickness
measurements may be used as a biomarker for study of hormone –
related malignancy, including breast, ovarian, endometrial and even
colon cancer.
2                      This study aimed to validate the transvaginal ultrasound
measurement of endometrial thickness in postmenopausal women by
demonstrating relationships between endometrial thickness
measurements and risk factors known to be associated with estrogen
exposure. As endometrial thickness measured by transvaginal ultrasound
relates to the status of estrogen it was correlated with serum estrogen
levels . Endometrial thickness assessment by transvaginal ultrasound is a
simple non invasise method which indicates estrogen levels in
postmenopausal women.
3REVIEW OF LITERATURE
History of ultrasound
The word sonar stands for sound navigation and ranging. Sonar
utilizes a frequency of 3.5 MHz to 10 MHz beyond the range of human
audibility. Ultrasound travels at a speed of 1560m/s in human tissue.
Sergal Sokolovin a Russian scientist is called the father of
ultrasound. He emphasized the potential importance of Sonar in 1929.
Dr Karl Dussik in Austria applied ultrasound in medical
diagnosis. In 1951, Wild and Reig reported a 90% accuracy in the
diagnosis of cystic versus solid lesions of various organs using the scan
technique.
In 1955, Ian Donald and Tom Brown designed the contact
scanner.  In 1961, Biparietal diameter was first measured by Ian Donald.
About this time, Campbell began working with the growth patterns of
fetus as measured by serial Biparietal diameter. In 1973, gray scale
presentation was introduced. Piezo electric effect was first discovered by
Pierre Curie in 1880.
4Transvaginal ultrasound was first introduced in 1984 by
Schwimmer S R and Lebovic J who used a 5 MHz, 13 mm transducer
that was not specifically designed for vaginal work.
TRANSVAGINAL SONOGRAM
As the endometrial histology can be predicted with accuracy
depending on the endometrial thickness and the internal architecture of
the endometrium, it actually became “sonomicroscopy”  wherein
structures that are not discernable with the naked eye could be
appreciated. Normal anatomy of the corpus uteri varies with age and
parity. Length of the uterus in various age groups are:
Post pubertal Reproductive Postmenopausal
5 – 6 cm 7 – 8 cm 4 – 6 cm
The echogenecity and thickness of the normal endometrium will
vary depending on the phase of the menstrual cycle. The normal
endometrial thickness  during the various phases of the menstrual cycle
and during the perimenopausal period are given in the following table.
5The thickness is measured in the long axis from basalis to the
contralateral basalis. The measurement should include only tissue and
not fluid.
Phase Thickness mm
Menstrual 2 – 4
Early proliferative 4 – 6
Periovulatory 6 – 8
Secretory 8 – 14
Postmenopausal 4 – 8
Postmenopausal with hormone
replacement therapy
4 – 10
Tissue insufficient for diagnosis < 4 – 5
6Not only the thickness, the echogenecity of the endometrium has
certain specific charecteristics during the various phases of the
menstrual cycle, thus enabling the histology of the endometrium to be
evaluated with precision by examined with the transvaginal sonogram.
During the menstrual phase – the  endometrium appears as an
echogenic uninterrupted layer of 1 – 4 mm in the total anteroposterior
width.
Grunfeld in 1991 has described three patterns in evaluating
changes in the normal endometrium.
Pattern 1:
During the early proliferative phase the thickness is 2 – 4 mm.
Endometrium functionalis is hypoechoic or  isoechoic and endometrium
basalis is somewhat echogenic.
Pattern 2:
Ultrasound appearance of late follicular endometrium is
characterized by three layers. Trilaminar appearance or triple sign.
Middle layer  represents the lumen of the endometrial cavity. The
lumen is echogenic because the endometrium is coated with mucous that
7acts as an interface and reflects ultrasound. Surrounding the lumen is the
hypoechoic endometrium functionalis and the echogenic endometrium
basalis. There is an increase in echogenecity from the basal layer
upwards but the inner layer still has some hypoechogenic changes.
The endometrium functionalis is hypoechoic in the follicular
phase because of the edematous stroma and the lack of arteriole
invasion. The basalis is always echogenic because of increased edema
and vascularity of the basalis. In a normal cycle, the endometrial
thickness ranges from 6 – 12 mm in the late follicular phase.
Endometrium grows in the late proliferative phase at a rate of 0.5 mm/
day.
The trilaminar appearance is characteristic of the periovulatory
endometrium and was present in 92% of the late proliferative phase
biopsies  performed  by  Forrest  et  al.   Transmission    of  the  ultrasound
and posterior acoustic enhancement are also characteristic of follicular
phase and is present in 90% cases.
8Pattern 3:
In the secretory phase, the whole endometrium from the basalis to
lumen is very echogenic. The increase in echogenecity , most probably
is due to increase in luteal phase secretions and vascularity. The increase
in echogenicity is seen due to elevations in the progesterone but may
precede the rupture of follicle. Cul de sac fluid is often seen behind the
uterus on ultrasound  and helps to confirm that ovulation has occurred.
The endometrium achieves its greatest width in the mid secretory phase
measuring upto 14 mm in width.
In post menopausal women the endometrial thickness is usually  4
– 8 mm. the American College of Obstetrics and Gynaecology has
published a technical bulletin  on  gynaecologic ultrasound which sets
additional guidelines for transvaginal ultrasound.
Below a cut off of 4-5 mm in anteroposterior thickness of the
endometrium for women with postmenopausal bleeding, there may not
be significant associated pathology. Less than 4 – 5 mm or a thin pencil
line echo is usually associated with tissue insufficient for diagnosis.
9Those more than 5 mm may need endometrial sampling. Thus
transvaginl sonogram maybe helpful in distinguishing patients with
minimal endometrial tissue caused by postmenopausal atrophy and
patients with significant endometrial tissue or polyps and are in need of
further evaluation.
Transvaginal ultrasound of the pelvis is a highly reliable method
for detecting endometrial cancer. In patients with postmenopausal
bleeding, if the thickness of the endometrium is uniformly 5 mm or less,
the  probability  of  endometrial  cancer  is  less  than  1%.  Sampling  of  the
endometrium must be performed if there is diffuse thickening of the
whole endometrium or focal thickening of part of the endometrium
measuring 5 mm or more. The combination of abnormal vaginal
bleeding and an endometrial thickness 5 mm or greater is 92% sensitive
and 57% specific for endometrial cancer.
Transvaginal ultrasound may indicate the type of abnormality
seen within the endometrium—for example, endometrial hyperplasia,
polyps, or carcinoma. Classically, endometrial hyperplasia affects the
entire  endometrium  and  results  in  widening  of  the  endometrium.  The
endometrial hyperplasia has a cystic lace-like appearance on ultrasound.
Endometrial polyps manifest as focal areas of endometrial thickening,
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and the stalk of the polyp may be seen if sufficient fluid is present in the
endometrial cavity. Endometrial carcinoma may occur in the form of a
polyp, within endometrial hyperplasia, or as a heterogeneous
endometrial mass with a widened irregular cavity. Pathological
confirmation of the histology is needed in all cases, as the ultrasound
appearances overlap considerably. Endometrial biopsy is performed if
the endometrial cavity is irregular, the endometrium has diffuse or focal
widening greater than 5 mm, or if the whole endometrium has not been
adequately assessed.
Transvaginal ultrasound may also identify ovarian pathology,
including polycystic ovaries in younger women and ovarian tumours
secreting oestrogens, causing abnormal vaginal bleeding. The ovaries
are atrophic in most postmenopausal women and cannot be identified on
ultrasound in up to 20% of women.
NORMAL ENDOMETRIAL LINING
 ENDOMETRIAL HYPERPLASIA
ENDOMETRIAL POLYP
ENDOMETRIAL CARCINOMA
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In patients with endometrial carcinoma invasion into the
myometrium can be determined. Loss of the subendometrial halo,
consisting of compact myometrium is the first ultrasonic feature of
invasion.
With more advanced myometrial invasion a distinct tumour –
myomtrial interface can be visualized. Schoenfeld et al measured
invasion from the endometrial lumen to the most distant tumor interface.
This measurement divided by the total thickness of the uterine
myometrium or the total anteroposterior uterine distance is divided by
the total endometrial width. If this ratio exceeds 30%, myometrial
invasion is suspected.
According to the latest FIGO classification, the depth of
myometrial invasion distinguishes stage IB of endometrial cancer from
stage IC. Gordon et al determined preoperative assessment of
myometrial invasion by transvaginal sonogram in a group of 25 patients
with histologically proven endometrial cancer and found that in 85%
cases, transvaginal sonogram correctly predicted the depth of
myometrial invasion within 15% of the actual measurement.
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Transvaginal sonogram was accurate in 16 cases over diagnosis in
3 cases. Therefore sensitivity of transvaginal sonogram in detecting deep
invasion was 100%, specificity more than 80% and accuracy 84%.
Cacciatore et al used preoperative ultrasonogram to stage 93
patients with endometrial cancer and were able to predict correctly
myometrial invasion I 80%. Sonographic staging was accurate in 90%
cases.
Transvaginal ultrasound of the pelvis is a highly reliable method
for detecting endometrial cancer. In patients with postmenopausal
bleeding, if the thickness of the endometrium is uniformly 5 mm or less,
the  probability  of  endometrial  cancer  is  less  than  1%.  Sampling  of  the
endometrium must be performed if there is diffuse thickening of the
whole endometrium or focal thickening of part of the endometrium
measuring 5 mm or more. The combination of abnormal vaginal
bleeding and an endometrial thickness 5 mm or greater is 92% sensitive
and 57% specific for endometrial cancer.
Transvaginal ultrasound may indicate the type of abnormality
seen within the endometrium—for example, endometrial hyperplasia,
polyps, or carcinoma. Classically, endometrial hyperplasia affects the
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entire  endometrium  and  results  in  widening  of  the  endometrium.  The
endometrial hyperplasia has a cystic lace-like appearance on ultrasound.
Endometrial polyps manifest as focal areas of endometrial thickening,
and the stalk of the polyp may be seen if sufficient fluid is present in the
endometrial cavity. Endometrial carcinoma may occur in the form of a
polyp, within endometrial hyperplasia, or as a heterogeneous
endometrial mass with a widened irregular cavity. Pathological
confirmation of the histology is needed in all cases, as the ultrasound
appearances overlap considerably. Endometrial biopsy is performed if
the endometrial cavity is irregular, the endometrium has diffuse or focal
widening greater than 5 mm, or if the whole endometrium has not been
adequately assessed.
Transvaginal ultrasound may also identify ovarian pathology,
including polycystic ovaries in younger women and ovarian tumours
secreting oestrogens, causing abnormal vaginal bleeding. The ovaries
are atrophic in most postmenopausal women and cannot be identified on
ultrasound in up to 20% of women.
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Procedure of transvaginal sonogram:
Until recently, the primary method for detecting
gynaecologic pathology was bimanual pelvic examination, with
confirmatory or additional information supplied by transabdominal
ultrasound.
Despite technical advances, transabdominal ultrasound imaging of
the female reproductive tract was limited by attenuation of the sound
beam  by  tissues  of  the  anterior  abdominal  wall,  distended  urinary
bladder, precluding the use of high frequency transducers (5 MHz) and
the inability to correlate areas of visible pathology with direct palpation.
Image resolution has improved dramatically with the introduction of
transvaginal sonogram. The transducer is closer to the pelvic organs,
higher frequencies can be used, reducing attenuation of the sound beam
resulting in improved overall image quality.
Descriptions of the endometrium on ultrasound examination
include global thickening, heterogeneity, thickening, focal areas of
thickening, fluid collections, increased vascularity and myometrial
associated findings such as myometrial cysts, and submucosal fibroids.
After menopause, endometrial thickening may reflect proliferative
18
endometrium, cystic hyperplasia, complex hyperplasia, atypical
hyperplasia, or carcinoma of the endometrium. Ultrasound evidence of
thickened endometrium may also indicate structural abnormalities such
as a uterine septum, submucous myomas, polyps, or adenomyosis.
Ultrasound technology, by identifying vascular flow, now allows
differentiation of polyps from other abnormalities. Increased vascularity
and fluid accumulation in association with endometrial thickening are
cause for greater concern than other findings.
Patient preparation:
Patient is informed about the procedure. She is asked to empty the
bladder completely. This contributes greatly to patient comfort and
acceptance of the technique. The best position is the dorsal position
employed for vaginal examination. A transabdominal ultrasound is done
prior to the vaginal study to exclude large masses and if the uterus is
more  than  19  cms,  as  in  such  conditions  the  vaginal  study  will  be
suboptimal due to its limited field of view. In all other cases, trans
vaginal sonogram can be performed in lieu of abdominal scanning.
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Transducer preparation:
Vaginal transducers are between 5 – 7.5 MHz in frequency. The
size of the sector image is usually between 90- 115 degrees. The image
is produced from an end firing transducer or a transducer that is angled
upto 30 degrees off axis. Focal zones range from 1 – 8 cm. The
transducer should be covered by a condom filled with approximately 5
ml of ultrasonic gel. Condoms that contain spermicidal agents should be
avoided in cases of infertility.
Additional gel may be applied to the outside of the condom prior
to its insertion, but this should be omitted in cases of infertility.
Following completion of examination, the transducer assembly should
be immersed in disinfectant for 10 minutes.
Probe manipulation:
Uterine corpus is an important structure in transvaginal sonogram
and serves as a useful anatomic landmark for targeted organ imaging.
Transducer orientation is unique in vaginal scanning, with the
longitudinal plane directed from the patient’s feet to her head.
Transverse scans are obtained in a coronal plane by rotating the
transducer 90 degrees counterclockwise. Adnexa are optimally imaged
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by positioning the transducer somewhat obliquely towards the
contralateral side.
Confusion  can  also  occur  because  of  the  actual  position  of  the
ultrasound beam which is 90 degrees off axis from the image on the
monitor. This results in the longitudinal images being displayed on the
monitor in a 90 degrees counterclockwise rotation from their actual
position.
Ultrasound transducers have a reference mark. With the reference
mark pointing up, left side of the screen represents a cephalad
orientation and the top of the screen represents the anterior abdominal
wall. With this view, an anteverted uterus points up and to the left while
a retroverted uterus points down and to the right.
Anatomic changes due to scanning with an empty bladder must
also be considered when performing a vaginal ultrasound. The uterine
fundus becomes much more anteverted. In addition the ovaries often
change their position following bladder decompression.
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Sliding test:
It may be helpful to place one hand on the patients lower
abdomen  while  performing  the  transvaginal  sonogram  in  an  effort  to
optimally position the ovaries in the transducer’s field of view. Also
areas of focal tenderness can be elicited with the movement of the
transducer. Transvaginal sonogram can also be used in the follow up of
women  on  Tamoxifen  therapy  for  breast  cancer  and  women  on
hormonal replacement therapy after menopause.
Postmenopausal endometrium and estrogen levels:
Endometrial cancer is a disease that occurs primarily in
postmenopausal women and is increasingly virulent with advancing age.
The role of estrogen in the development of most endometrial cancers has
clearly been established. Any factor that increases exposure to
unopposed estrogen increases the risk for endometrial cancer.
Serum estrogen levels decreases in postmenopausal women.
Endometrial thickness is considered as a marker for estrogen status in
postmenopausal women which can be measured by a transvaginal
ultrasound.
22
Literature  review  shows  that  postmenopausal  patients  with  a
thickened endometrium (>5 mm) have significantly higher rates of
endometrial cancer than patients with normal endometria. Many
institutions have adopted a measurement of ?5.0 mm or less to exclude
patients from the need of pathologic evaluation. However, concerns
have been raised about using transvaginal ultrasound as the sole method
of evaluating endometrial pathology when focusing only on endometrial
thickness. Uterine fibroids, hypertension, diabetes, obesity, the dosage
of hormone replacement therapy (HRT) and other gynecologic factors
increase endometrial thickness.
The mechanism for this increase in endometrial thickness is
thought to be related to increased levels of circulating or local estrogens.
For instance, Gull et al reported that uterine fibroids were associated
with increased endometrial thickness, which could be attributed to the
estrogen and progesterone receptors within the fibroids. Obesity also
contributes to lower blood sex hormone binding globulin levels, insulin
resistance, diabetes and high blood pressure. As a result, there is a
shared association between obesity and altered estrogen levels that is
partly responsible for increased endometrial thickness.
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Reports of the incidence or true effect of co-morbidities such as
obesity and diabetes on endometrial thickness and endometrial
pathology are limited and contradictory. In fact, Gull et al found that
risk factors previously shown to be associated with an increased risk for
endometrial cancer such as obesity, hypertension and diabetes mellitus,
were not shown to influence endometrial thickness. Incongruities
between the studies and the lack of data reported encouraged to
determine the effect that confounding risk factors have on the
endometrial thickness and subsequent endometrial pathology.
CHARACTERISTICS RELATIVE RISK
Nulliparity 2-3
Late menopause 2-4
Obesity 21 - 50 lbs overweight 3
>50 lbs overweight 10
Diabetes Mellitus 2.8
Unopposed estrogen therapy 4-8
Tamoxifen therapy 2-3
Atypical endometrial hyperplasia 8-29
HNPCC Syndrome 20
24
Other factors leading to long term estrogen exposure such as
polycystic ovary syndrome and functioning ovarian tumors are also
associated with an increased risk of endometrial cancer other medical
conditions such as hypertension and hypothyroidism have been
associated with endometrial cancer, but a causal relationship has not
been confirmed.
The guideline of the Dutch Society of Obstetrics and Gynecology
does, among many other guidelines, recommend that endometrium
sampling is not indicated if transvaginal ultrasonography shows a
double layer less than 5 mm. Therefore, histology was obtained when
the endometrial thickness exceeded 4 mm. This might have led to
verification bias, which occurs when verification of the diagnosis
depends on the test under study. Information on the subsequent
development of a malignancy in the women with reassuring results at
first diagnoses was not obtained unless they had recurrent bleeding. It is
important to realize that further assessment of the endometrium was
only dependent on the findings at ultrasonography and not on other risk
indicators assessed in the present study, such as obesity, diabetes, or
25
hypertension, thus limiting the impact of verification bias on other
findings.
In  the  literature,  the  accuracy  of  a  diagnostic  test  is  commonly
reported in terms of sensitivity, specificity, and likelihood ratios. When
such parameters are used, the crucial underlying assumption is that these
indices remain constant for patients with different clinical
characteristics.A diagnostic test should decrease the posttest risk of the
presence of endometrial cancer to a level of approximately 5%, not only
when used in women with a low pretest change for atypical hyperplasia
or  a  malignancy  of  the  endometrium,  but  also  in  women  with  a  high
pretest change. In women with a negative test (eg, in those with
endometrial thickness under a certain cutoff point), further invasive
diagnostic procedures can be omitted.
First, the incidence of malignancy is higher in women with
postmenopausal vaginal bleeding and obesity (18%) or diabetes (21%),
compared with women without one of these risk factors (8.0%).
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In obese women with diabetes, the incidence was as high as 29%.
Second, in the absence of malignancy, symptomatic women with obesity
and/or diabetes have thicker endometria than women without these risk
factors. In women diagnosed with a malignancy, endometrial thickness
did not differ between patients with or without risk factors. Thus,
whereas the pretest probability for malignancy was higher, the potential
of the test to reduce the posttest probabilities to less than 5% was very
limited.
Previous reports on this topic are scarce. In a sample of 559
asymptomatic postmenopausal women with (33%) or without HRT, the
current use of HRT was the most important factor associated with
endometrial thickness. Others found increased endometrial thickness in
asymptomatic obese postmenopausal women.
Van der Bosch et al, who reported a significant positive
correlation between both weight (0.24, P < .01) and BMI (0.26, P < .01)
and the endometrial thickness in postmenopausal women with vaginal
bleeding or endometrial cells on cervical cytology smear.
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It is not clear that diabetes and obesity are independent factors
that affect the diagnostic accuracy of transvaginal ultrasonography, and
a synergistic effect cannot be excluded. There has been a reported
decrease in the accuracy of transvaginal ultrasonography in obese
women with diabetes compared with obese women without diabetes, for
a strong increase in the incidence of cancer, thus indicating an
independent effect. However, because of the relatively small number of
patients with combined risk factors in various study cohorts, definite
conclusions on this topic cannot be drawn.
The relation between endometrial thickness and hypertension has
been examined in asymptomatic women. After correction for weight,
Serdar Serin et al, found no relation between hypertension and
endometrial thickness.
Pardo et al showed that, in women with an endometrial thickness
exceeding 7 mm, endometrial atrophy was present in 84% of the patients
on nifedipine, compared with 41% of women not on antihypertensive
drugs. They stated that a drug effect on the endometrium caused a false-
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positive test in women on nifedipine comparable with the phenomenon
described for tamoxifen.
Endometrial sampling is the ‘‘gold standard’’ for diagnosing
abnormalities in the endometrial tissue of patients with PMB. Since the
sensitivity of endometrial sampling has been estimated to range from
85% to 95%, there has been a growing trend toward using a noninvasive
procedure, such as high-resolution transvaginal sonography (TVS), to
measure the endometrial thickness and to classify cases as being at low
or high risk for malignancy, thus avoiding unnecessary sampling
(Taipale et al., 2004).
Trans-vaginal ultrasonography can reliably assess thickness and
morphology of the endometrium and can thus identify a group of
women with postmenopausal bleeding who have a thin endometrium
and are therefore unlikely to have significant endometrial disease. This
group may not require any further investigation unless there is a
recurrence of the bleeding (WHO, 1996).
The recent Scottish intercollegiate guideline network (SIGN)
recommends that a trans-vaginal ultrasound scan should be the first line
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investigation (Fornander et al., 1989). It is conventional to measure the
thickness of both endometrial surfaces together (double thickness) at the
thickest point in the mid-sagittal view assuming that the endometrial
morphology is consistent throughout (WHO, 1996).
Some authors have revealed a relationship between the TVS
determined endometrial thickness and histopathological findings.
However, cutoff values of endometrial thickness below which cancer
can be excluded have varied considerably (Gupta et al., 2002 and
Bruchim et al., 2004).
Karlsson et al. (2001) could not find any association between
endometrial thickness and smoking, late menarche, or early menopause,
but parity was the most important factor associated with endometrial
thickness. On the other hand, Gull et al. (2001) found that parity had an
influence on uterine width and significantly associated with uterine size
but it had no association with uterine length and endometrial thickness.
There are several factors known to be associated with endometrial
cancer, e.g. obesity, early menarche, nulliparity, infertility, late
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menopause, diabetes mellitus, hypertension, and use of hormone
replacement therapy (HRT) (Gull et al., 2001).
It is known that multiparity, smoking, late menarche and early
menopause are inversely associated with the risk of endometrial
carcinoma (Levi et al., 2003).
Several studies have shown that the risk of the development of
endometrial cancer is associated with increased endometrial thickness.
(Ylostalo et al., 2003), and it is correlated furthermore with serum
estradiol in premenopausal women, but in postmenopausal women
serum estradiol mostly originates from a conversion of estrone in
adipose tissue.
The few studies that have examined the relationship between
endometrial thickness and body mass index (BMI) in postmenopausal
women have shown that these two factors are related significantly
(Andolf et al., 2004). Some studies have indicated that central adiposity
is a strong and independent risk factor for endometrial cancer. High
body mass index and abdominal fat distribution correlate with increased
endometrial thickness and bone mass (Douchi et al.,)
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Pathological conditions:
Recent studies with transvaginal ultrasound suggest that this
modality may be of use in detecting endometrial abnormalities like
polyps, endometritis, hyperplasia and carcinoma Leiomyoma are seen as
echo dense defects within the myometrium. They are typically so dense
that shadowing is apparent distal to the fibroid. Endovaginal sonography
offers the opportunity to visualize the relationship of the fibroid to the
endometrial cavity.
Adenomyosis do not have clear orders and are less dense than
leiomyomata. They do not shadow like fibroids and are commonly
cystic. They are seen as mottling within the myometrium. They may
present as a myometrial mass or if glands begin secreting as cystic
structures within the inner myometrium.
Endometrial filling defects – endometrial polyps are seen as
endometrial filling defects. Scanning for endometrial contour defects
should be done in the follicular phase because the hypoechoic
endometrium serves to contrast against echogenic masses. The presence
of a filling defect is 70% sensitive and 95% specific when compared
with hysterosalpingogram. ( Blumenfeld and Turner 1996)
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AIMS OF THE STUDY
1. To validate transvaginal ultrasonographic measurement of
endometrial thickness   as a biomarker of estrogen exposure in
postmenopausal  women.
2. To correlate serum estradiol  levels with endometrial thickness.
3. To study association between endometrial thickness and risk
factors associated with   estrogen exposure.
32
MATERIALS AND METHODS
Study population – 150 postmenopausal women in the age group 50 to
70 years.
Study carried out in Government RSRM Hospital after Ethical
committee clearance during the period January 2010 to October 2010.
Data Collection - A self administered baseline questionnaire done
before ultrasound screening gave information on age, years since
menopause, body weight, height and medical disorders like diabetes and
hypertension.
After informed consent and clinical examination, endometrial
thickness is measured in longitudinal axis with real-time
ultrasonography with a 7.5MHz transvaginal transducer.
Serum estradiol levels are measured by chemiluminescent
immunoassay method and correlated with endometrial thickness.
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Selection Criteria:
         Women with natural menopause, not on HRT.
Exclusion Criteria:
        Women on current treatment for cancer, recent tamoxifen use,
participation in another cancer screening or primary prevention study.
Method:
A 7.5 MHz transvaginal  sector  probe with phased array and end
firing potential was used.
All the patients were asked to empty their bladder prior to the
examination.
The probe was covered with a sterile sheath or condom containing
the acoustic gel.
The scan was performed with the patient in a supine position.
The transducer was introduced into the posterior vaginal fornix.
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The uterus was scanned in the long axis and coronal views with
special emphasis on endometrium. The scanning of the uterus was done
first in the sagittal plane from the fundus to the internal os. Regularity of
the uterus noted. The length, anteroposterior measurements and
transverse dimensions of the uterus were noted and endometrial volume
calculated.
Anteroposterior measurements of endometrial thickness were
taken from basalis to contralateral basalis in the long axis of the
endometrium. Oblique semicoronal views should be avoided as this may
cause the endometrium to appear thicker.
Uterine cavity was examined systematically in both the sagittal
and coronal views for the presence of submucous fibroid polyps,
endometrial polyps, adenomyosis and endometrial architecture.
If there is suspicion of endometrial carcinoma, evidence and
extent of myometrial invasion when present was noted. Now the probe
was  angled  to  the  right  or  left  of  the  midline  in  the  sagitttal  plane  to
image the ovaries. The internal echotexture of the ovaries were also
imaged and any abnormalities were noted.
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The entire pelvis was additionally examined to rule out any other
pathology.
The results of the transvaginal sonogram were interpreted as:
Normal endometrium
Thickened endometrium echo or abnormal endometrial
architecture
Endometrial polyps
Pyometra
Endometrial carcinoma
          Submucous fibroid
36
ANALYSIS AND OBSERVATIONS
TABLE 1: ENDOMETRIAL THICKNESS AND SERUM
ESTROGEN LEVELS
Number
of cases
Percentage of
cases
%
Endometrial
thickness
Mean thickness
in mm
Serum
estrogen levels
Mean in pg/ml
107 71.3 3.75 14.6
12 8 12.2 18.25
24 16 14.8 32.45
7 4.7 16.7 38.36
Table 1: The endometrial thickness measurements in the study group
and their respective serum estrogen levels are tabulated. The serum
estrogen levels are high in patients with increased endometrial thickness.
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107 Patients (71.3%) had mean endometrial thickness of 3.75mm.
12 Patients(8%) had mean endometrial thickness of 12.2mm.
24 Patients (16%)had mean endometrial thickness of 14.8mm
7 Patients(7%) had mean endometrial thickness of 16.7mm.
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Among the 150 cases, 71.3% of cases had a mean endometrial
thickness of 3.75 mm with mean serum estrogen levels of 14.6 pg/ml.
12% of the patients had a mean endometrial thickness of 12.2.mm with a
mean estrogen level of 18.25 pg/ml. 24% of the patients had a mean
endometrial thickness of 14.8 mm with mean estrogen level of 32.45
pg/ml.7% of the patients had a mean endometrial thickness of 16.7 mm
with mean estrogen level of 38.36 pg/ml.
Thus patients with increased serum estrogen levels had
endometrial thickness more than 5 mm.
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TABLE 2: RISK FACTORS AND ENDOMETRIAL THICKNESS
RISK FACTOR N=150 Percentage
of cases %
ET>3mmm
%
P
value
   Diabetes Ever 48 34 70 0.21
Never 102 66 66.8
Hypertension Ever 27 18 69.8 0.04
Never 123 82 65.9
Table 2: The risk factors are diabetes and hypertension. The P value is
statistically significant for the risk factor hypertension in the study
group.
The number of patients with diabetes among the group was
48(34%) and  P value was 0.21 correlating the endometrial thickness
and the risk factor diabetes.
Among the 150 cases, 27patients (18%) had hypertension and P
value was 0.04 correlating endometrial thickness and hypertension
which was statistically significant.
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66 % of patients were non-diabetics
34% of patients were diabetics
41
82 % of patients were non-hypertensives
18 % of patients were hypertensives
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Table 3: AGE DISTRIBUTION AND ENDOMETRIAL
THICKNESS
RISK FACTOR n=150 ET>3 mm P value
AGE
50-54 56 71.7
0.0355-59 39 66.9
60-64 33 62.8
65-70 22 58.7
Table 3: The age of patients and the endometrial thickness
measurements are tabulated above.
The endometrial thickness was correlated with the age of the
patient and the P – value was 0.03, which was statistically significant.
The lesser the age of the patient the more the endometrial thickness.
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Table 4: AGE AT MENOPAUSE AND ENDOMETRIAL
THICKNESS
RISK FACTOR n= 150 ET >3 mm
%
P value
AGE AT
MENOPAUSE
< 40 24 60.3
0.0641– 49 43 70.2
>50 83 70
The age at which menopause was attained and the endometrial thickness
measurements were correlated. The P value was statistically significant.
The age at which menopause was attained and the endometrial thickness
was correlated among the patients. The endometrial thickness was more
among the patients with late onset of menopause.
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TABLE 5:  BODY MASS INDEX AND MEAN ENDOMETRIAL
THICKNESS
PERCENTAGE OF
CASES
n = 150
BMI MEAN
ENDOMETRIAL
THICKNESS IN mm
24% <23 3.4
36% 23 – 26 6.2
28% 26 -  29 11
12% >29 13.4
Table 5: The body mass index distribution among the study group and
the respective mean endometrial thickness are tabulated above.
Increased endometrial thickness was found in patients with increased
BMI.
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Body mass index – BMI was calculated using the QUETELET
index. BMI = weight in kg/ height in cm2 .
The patients were divided into four groups according to the BMI.
24% of the patients had BMI less than 23 with endometrial thickness of
3.4 mm. 36% of patients with BMI 23 – 26 had endometrial thickness of
6.2 mm. 28 % of patients with BMI 26 – 29 had endometrial thickness
of  11  mm.  12  %  of  patients  had  a  BMI  of  more  than  29  and  an
endometrial thickness of 13.4 mm. Thus patients with increased BMI
had increased endometrial thickness.
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RESULTS
Table1: Endometrial thickness and serum estrogen levels
From the present study, 71.3% of patients with mean endometrial
thickness of 3.75 mm had serum estrogen level of 14.6 pg/ml, 8% of
patients with mean endometrial thickness 12.2mm had a serum estrogen
level of 18.25pg/ml. 16% of patients had a mean endometrial thickness
of 14.8mm and serum estrogen levels of 32.45pg/ml. 7% of patients had
a mean endometrial thickness of 16.7mm and a serum estrogen level of
38.36pg/ml.
Thus estrogen levels are high in patients with increased
endometrial thickness.
Table 2: Risk factors and Endometrial thickness
The risk factors studied were diabetes and hypertension. Among
the study group34% were diabetics, and 18% were hypertensive. The
endometrial thickness was statistically significantly higher (p= 0.04) in
the hypertensives. In the diabetes the endometrial thickness was not
statistically significant (p = 0.21).
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Table 3: Age distribution and endometrial thickness
The endometrial thickness was correlated with the age of the
patient, with younger patients having a thicker endometrium (p=0.03).
Table 4: Age at Menopause and endometrial thickness
The age at which menopause was attained and the endometrial
thickness correlated among the patients. The endometrial thickness was
more among the patients with late onset of menopause (p=0.06)
Table 5: Body Mass Index and Endometrial thickness
24% of patients had BMI less than 23, 36% had a BMI of 23 to
26, 28 % patients had a BMI of 26 to 29 and 12% had a BMI more than
29. Increased endometrial thickness was found in 40% of the patients
with increased BMI.
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DISCUSSION
To validate transvaginal ultrasound measurement of endometrial
thickness as a surrogate marker of estrogen status, in the present study
the association between endometrial thickness and  factors known to be
associated with estrogen status in postmenopausal women were studied.
From the present study a strong and consistent association between
endometrial thickness and factors reflecting estrogen exposure was
observed. Other studies have described similar associations involving
endometrial thickness, diabetes hypertension, and BMI.
        Studies about serum estrogen levels and endometrial thickness and
which correlate with present study are:
        1)Postmenopausal serum estradiol determination and endometrial
thickness-Angel Cho and Chiehuan Ed Hsu et al.In this study,patients
with less endometrial thickness had mean estrogen level of about 15.75
pg/ml which is consistent with the present study.5% of the patients in
that study had endometrial carcinoma with mean endometrial thickness
of 18.8mm and serum estrogen level of 37.48pg/ml which correlates
with the present study.
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        2)Endometrial thickness in postmenopausal women as a marker for
estrogen exposure-2004; Hill and Martin study. The frequencies of
endometrial thickness with serum estrogen levels were 69% had mean
estrogen level of 13.8 pg/ml,6% with 19.25 pg/ml,21% with
30.2pg/ml,and 4% with 39.6pg/ml. These results are consistent with the
present study.
3) Judd and Frumer study-Origin of serum estrodiol in
postmenopausal women.Among the study group 69% of the patients had
serum estrogen levels of 16.75pg/ml with thinner endometrium.
        In postmenopausal women not receiving HRT, serum estrogen
concentrations increase with body weight due to peripheral
aromatization of ovarian and adrenal androgens in adipose tissue.
Studies which corelate endometrial thickness and BMI are
1)Katanozaka and Douchi study-Relationship between BMI and
transvaginal ultrasound endometrial thickness in postmenopausal
women.The frequencies of thicker endometrium according to body mass
index quartile (<23 ,23-26,26-29,>29) are 55.2%,66.1% ,69.7%,and
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76.7%.Thus patients with increased BMI had  increased endometrial
thickness which is consistent with the present study.
2)Andolf and Aspenberg study(1993)-Ultrasonic thickness of the
endometrium correlated to body weight in postmenopausal
women.According to this study the distribution of thicker endometrium
among the BMI quartiles were 4.2mm,7mm,12.8mm,and 14.6mm,which
is consistent with the present study.
3)Van den Bosch et al-Age, weight, body mass index and endometrial
thickness  in  postmenopausal  women.  In  this  study,  age  of  the  patient,
weight, body mass index were tabulated against endometrial thickness.
The lesser the age of the patient the more is the endometrial thickness
which correlates with the present study. This study reported a significant
positive correlation between body weight (0.24,P<0.01), BMI
(0.26,P<0.01) and endometrial thickness. Thus the present study
correlates with the above study.
The risk factors like diabetes and hypertension associated with
increased endometrial thickness are correlating with studies like Matela
et al, Salmi et al and Diaz studies which found association between risk
factors like Hypertension, Diabetes and endometrial thickness.
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Likewise other sources of information support associations
involving endometrial thickness, age, uterine fibroids, hypertension and
diabetes. Decreasing endometrial thickness with increasing age and
increasing duration since menopause may reflect age and menopause
related declines in ovarian function and blood estrogen levels. Like
endometrium, uterine fibroids may contain estrogen and progesterone
receptors. Hypertension and diabetes are endometrial cancer risk factors.
Obesity, especially central obesity, contributes to lower blood sex
hormone binding levels, insulin resistance and high blood pressure. A
shared association with obesity and altered estrogen status explains, at
least in part, the apparent effect of history of hypertension and diabetes
on increased endometrial thickness.
In studies of women with postmenopausal bleeding and often
endometrial hyperplasia, ultrasound measurements of endometrial
thickness seems reproducible , with intra observer variation usually less
than 5 % and inter observer variation in the range of 5 – 10 %. A large
inter observer variation, relative to intra observer variation, suggests that
operative skill and experience may affect the ultrasound measurement of
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endometrial thickness. In contrast, fewer studies have evaluated the
reproducibility of  transvaginal ultrasound measurements of endometrial
thickness in asymptomatic postmenopausal women, who have, on an
average, atrophic endometria.
In clinical practice, the endometrial thickness measurement may
be used to monitor women on HRT, to evaluate women with
postmenopausal bleeding and to select women for more definitive
procedures such as dilatation and curettage, hysteroscopy or endometrial
biopsy. These latter procedures, in turn, constitute the gold standard for
measuring endometrial thickness and recognizing pathologic states
involving the endometrium. Recognizing these limitations, future
applications using transvaginal ultrasound endometrial thickness
measurements as a potential estrogen – related biomarker should
consider the role of these more definitive diagnostic procedures in
women with increased endometrial thickness.
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Using information prospectively collected on a large sample of
postmenopausal women recruited from the general community, we
observed consistent and biologically plausible associations involving
various risk factors and a single transvaginal ultrasound measurement of
endometrial thickness. These findings validate, transvaginal ultrasound
measurements of endometrial thickness as a measurement tool to
validate endometrial thickness in postmenopausal women.
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SUMMARY
1. From  the  study,  serum  estrogen  levels  co-related  well  with
endometrial thickness in postmenopausal women.
2. The risk factors associated with estrogen exposure studied are age
of the patient, age at menopause, diabetes, hyper tension and
BMI. The statistically significant risk factors in the study group
are age of the patient, age at menopause, hyper tension and
increased BMI.
3. Thus transvaginal ultrasound measurement of endometrial
thickness is a validate tool to diagnose endometrial pathology in
postmenopausal women. It can be used as a first line procedure
before other invasive diagnostic procedures. Thus endometrial
thickness is a surrogate biomarker of serum estrogen level.
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CONCLUSION
From this study, the endometrial thickness measurements
correlated well with serum estrogen levels. Hence endometrial thickness
in postmenopausal women is a surrogate marker for estrogen status.
The risk factors associated with estrogen exposure and
endometrial thickness were also validated. P value less than o.o5 is
statistically significant. From this study the risk factors statistically
significant are age of the patient, age at which menopause was attained,
history of hypertension and increased body mass index.
With the advent of transvaginal sonogram gynaecologists now
have a simple outpatient method of studying the endometrium for
detecting malignant lesions or their precursors at an earlier stage in
postmenopausal women.
In postmenopausal women less than 5mm or thin pencil line
endometrial echo is usually associated with atrophic endometrium.
Endometrial carcinoma is diagnosed at an earlier stage by loss of the
subendometrial halo which indicates myometrial invasion.
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PROFORMA
NAME:                                                    AGE:                             I.P NO:
D.O.A:                                                                RESIDENCE:
D.O.D:
MENSTRUAL HISTORY:
Age of menarche:
Bleeding: profuse/ moderate/ scanty
Menstrual cycles:                  regular/irregular                                   /days
Dysmenorrhea:                             present/ absent
Intermenstrual bleeding:
Menopause:                                                years
TREATMENT HISTORY:
EARLIER CONTRACEPTIVE HISTORY
ORAL CONTRACEPTIVE PILLS
INTRAUTERINE CONTRACEPTIVE DEVICES
OBSTETRIC HISTORY:
Married life                             parity                           living children
Last child birth                                                             sterilization
PAST HISTORY:  Diabetes
                               Hypertension, Family history of Carcinoma
PERSONAL HISTORY:
PHYSICAL EXAMINATION:
General condition:
Nourishment:
Built:
Height:
Weight:
BMI:
PER ABDOMEN: PER SPECULUM  EXAMINATION
VAGINAL EXAMINATION:
INVESTIGATIONS:
Serum estrogen level:
Blood sugar:
Blood urea:
Serum creatinine:
VAGINAL SONOGRAPHY:
Uterus:
Endometrial thickness:
Cervix:
Right ovary
Left ovary

Sl.
No Name I.P.No.
Age Parity Menopause&
Risk factor Uterine size
Endometrial
Thickness
(mm)
Serum estrogen
levels pg/ml BMI
1. Veeramma
9386
55,P5L4 2 yrs back 7x4.3x2.4 13 36.8 30
2. Shankari
22960
50,P3L3 1yr
HT
6x4.3x2.6 1.1x1.1 8 11.2 28
3. Narasamma
10214
52 1yr
DM
5.4x3.5x2.1 8.0 15.6 22
4. Kandammal
10277
52,P6L6 8yrs 4x4.3x3.4 4 18.45 23
5. Muniammal
10349
50,P5L3 3yrs 4.1x1.9x1.1 6 16.6 25
6. Kuppammal
10977
47,P3L2 1yrs
DM
4.6x4.2x3.3 8 35.6 31
7. Andal
12187
50,P1L1 2yrs 4.7x2.5x2.8 8 21.5 26
8. Kamatchi
11898
49,P4L4 2yrs 2.8x3x2.9 8 18.9 24
9. Bhanumathy
11990
48,P2L2 11/2yrs
DM
4.3x3.2x2.6 8 14.2 26
10. Ranikutty
11501
48,P3L3 3yrs 4.7x3.3x2.0 8 14.8 21
11. Kamala
6869
60,Nullipara 4yrs
HT
9.4x4.7x4.3 16 16.6 24
12. Muniamma
9497
54,P2L2 2yrs 3.5x2.6x1.2 2 10.6 27
13. Rakayee
21865
49,P3L3 2yrs
DM
4.2x1.2x1.6 3 26.6 25
14. Shanthi
23793
52,P4L3 3yrs 4.2x2.6x1.2 2 16.8 22
MASTER CHART
15. Kathammal
13897
50,P6L6 2yrs back
HT
4.3x2.7x1.2 4 6.9 28
16. Selvi
14901
49,P5L4 4yrs
DM
5x2.2x1.2 5 8.65 24
17. Sundari
13741
50,P2L1 3yrs 3.6x2.4x1.2 5 10.2 21
18. Karupayee
8498
49,P4L2 3yrs
HT
3.4x2.4x1.6 4 10.4 23
19. Senthil
9430
49,P3L2 4yrs 4.2x2.1x1.8 4 14.8 23
20. Sivapayee
16981
48,P2L3 4yrs
DM
3.9x2.3x1.6 3 25.6 21
21. Kalairasi
17914
49,P3L1 4yrs 3.6x3.2x1.1 5 14.6 32
22. Laxmi Elumalai
7937
50,P6L6 2yrs 7.5x4.4x2.3 13 14.9 26
23. Kuppammal
9966
57 10yrs 8.4x4.1x4.4 18 16.9 24
24. Rajakumari
7891
51,P3L13 4yrs
DM
4.3x2.7x1.2 1.2 12.2 20
25. Kasthuri
7985
60,P3L3 9yrs 5x2.2x1.4 6 14.6 28
26. Krishnaveni
12143
49,P2L12 2yrs 5x3.8x2.2 14 14.68 27
27. Eswari
17149
47,P2L2 2yrs 4.1x2.7x1.1 3 39.36 31
28. Kamatchi
17497
62,P2L2 12yrs 3.6x2.9x1.4 4 26.6 25
29. Chittu
14923
60,P3L3 11yrs
DM
3.9x1.8x1.6 5 6.6 22
30. Pattu
16492
57,P8L6 8yrs 4.0x2.0x1.4 4 10.2 24
31. Karumari
12492
56,P4L4 7yrs back
HT
4.4x2.0x1.1 3 10.4 27
32. Irumayet
17391
60,P6L5 8yrs 3.9x2.0x1.6 5 12.4 26
33. Rani Jeyaram
12345
46,P8L6 2yrs
DM
4.8x2.3x1.1 5 11.2 21
34. Mariammal
7505
75,P3L3 30yrs 6.3x5.3x4.2 16 14.8 25
35. Manjula
8909
54,P2L2 4yrs 5x3.2x2.4 10 36.28 30
36. Angammal
12450
60,P4L4 6yrs
DM
6.4x3.2x3.4 6 14.62 25
37. Vasantha
7941
47,P4L4 2yrs 5.2x2.3x1.1 4 14.5 26
38. Ambika
17641
51,P5L5 2yrs 4.8x2.8x1.2 5 12.6 28
39. Sampoornam
12416
52,P2L1 6yrs
HT
4.6x2.1x1.3 5 30.2 23
40. Sornam
7916
53,P4L4 6yrs 4.0x2.5x1.4 5 12.6 20
41. Mariamma
7841
57,P8L7 10yrs
DM
6.4x2.3x1.1 10 15.2 24
42. Revathy
17621
47,P6L6 2yrs
DM
5.4x3.0x2.9 8 5.8 26
43. Saroja
14594
48,P4L4 2yrs 4.1x1.1x2.1 5 39.6 30
44. Pappa
13141
44,P2L2 1yrs 4.6x2.1x1.9 8 10.6 22
45. Pappamma
7941
51,P5L4 6yrs
HT
3.6x2.5x1.6 4 32.4 26
46. Rajathy
13141
48,P3L3 4yrs
DM
5.2x3.0x2.6 8 12.6 24
47. Kuppamma
16131
52,P6L5 6yrs back
HT
4.6x2.1x1.1 4 18.2 21
48. Ponnatha
14842
54,P6L6 4yrs 4.8x3.1x2.6 11 34.4 23
49. Ponnamma
1781
47,P5L4 2yrs
DM
6.4x4.2x2.1 12 14.2 27
50. Thirupura Sundari
15421
45,P1L1 2yrs
DM
4.1x3.5x2.4 10 8.8 21
51. Kasthuri
9299
42,P4L4 2 yrs
DM
4.1x1.8x1.2 5 35.6 30
52. Arasani
9298
45,P1L4 1yrs
DM
6.4x7.8x2.8 9 12.6 28
53. Chellamma
10215
42,P2L2 1yrs
HT
4.1x2.4x2.5 9 34.2 22
54. Devaki
9964
45,P1L1 8yrs 8.2x5.5x2.1 18 12.4 23
55. Rani Rethnam
9301
45,P4L4 3yrs
HT
4.1x3.3x2 9 16.6 25
56. Rajam
9965
44,P5L5 1yrs
DM
4.9x3.8x1.6 17 15.6 31
57. Rani
10217
44,P2L2 2yrs 4.2x3.6x2.1 10 18.2 26
58. Rani Renganath
10882
45,P3L3 2yrs
DM
8.6x4.4x5.1 10 32.5 24
59. Ruckmani
10972
48,P4L4 11/2yrs 6.8x3.5x2.0 11 16.2 26
60. Jamuna
10979
43,P3L3 3yrs
DM
6.2x5.3x4.2 16 12.2 21
61. Elliammal
8580
43,P3L3 4yrs 4.6x2.4x1.6 8 12..4 24
62. Radhamani
9293
53,P6L6 2yrs
DM
8.4x5.3x2.6 16 14.6 27
63. Rani
23214
44,P3L3 2yrs back
DM
4.6x3.3x2.0 9 10.5 25
64. Ruckmani
11212
48,P1L1 3yrs 8.1x4.7x4.2 27 10.6 22
65. Guna
11903
47,P4L4 2yrs
DM,HT
5.2x4.8x2.1 10 14.25 28
66. Uma
12248
43,P2L2 4yrs 4.5x3.2x1.9 10 14.8 24
67. Rani Shanmugam
11606
44,P2L2 3yrs 7.3x6.3x2.4 9 14.56 21
68. Ahima Bee
11846
43,P3L3 3yrs
HT
5.2x4.4x2.4 8 14.2 23
69. Dhanalakshmi
10916
42,P4L4 4yrs 7.0x6.3x2.5 19 12.6 23
70. Mallika
10208
43,P3L3 4yrs
HT
4.7x3.8x2.0 10 31 21
71. Rani Raghavan
1501
43,P3L3 4yrs
DM
4.7x3.3x2 8 11.2 32
72. Saraswathy
10807
44, 2yrs
DM
7.9x3.2x2.3 13 10.6 26
73. Nagammal
11460
44,P3L3 10yrs 6.5x3.9x4.6 8 16.8 24
74. Thangammal
7931
50,P8L8 4yrs
HT
6.6x3.9x4.6 10 16.2 20
75. Chellammal
6279
50,P7L7 9yrs 8.9x3.8x2.4 9 15.1 28
76. Vellammal
7938
44,P2L2 2yrs 6.4x3.2x2.4 10 30.5 27
77. Alamelu
11458
54,P5L5 2yrs
 HT
9.1x8.1x3.4 23 12.45 31
78. Rathinam
11463
42,P3L3 12yrs 7.5x4.0x4.2 10 12.9 25
79. Suseela
11785
48,P3L3 11yrs back
DM
8.4x4.0x3.2 8 14.6 22
80. Ramamani
26215
44, 8yrs
DM
8.9x4.9x5.8 18 16.3 24
81. Ellammal
12094
42,P4L4 7yrs 5.1x4.2x2.6 8 18.8 27
82. Syed Ali Fathima
12268
45,P3L3 8yrs
HT
4.0x3.1x2.4 8 12.4 26
83. Leela
74199
42,P3L3 2yrs
HT
8.0x4.2x3.2 11 11.6 21
84. Jeyammal
7520
44,P3L3 30yrs 10x5.1x3 10 31.2 25
85. Velammal
7938
42,P2L2 4yrs 4.0x4.2x2.5 8 10.8 30
86. Kuppammal
Parthiban
11523
45,P2L2 6yrs
DM
7.0x4.2x3.2 8 12.8 25
87. Pattu
15187
43,P3L3 2yrs
DM
5.1x4.2x2.5 7 12.2 26
88. Rajakumari
6916
44,P4L4 2yrs 4.6x4.2x2.6 8 16.2 28
89. Jamuna Bai
7918
43,P2L2 6yrs 6.8x3.5x2.4 16 9.8 23
90. Santhanam
18431
54,P3L3 6yrs
HT
6.4x5.2x4.3 20 12.4 20
91. Murugammal
17341
47,P3L2 10yrs
DM
5.4x4.3x3.24 8 13.5 24
92. Vani
17324
51,P2L2 2yrs
DM
4.8x3.6x2.6 10 16.65 26
93. Lakshmi
17841
48,P4L4 2yrs 4.9x3.4x2.4 11 12.4 30
94. Sivakami
15941
47,P4L3 1yrs 4.1x3.6x2.1 7 10.2 22
95. Sridevi
16491
48,P4L3 6yrs back
HT
4.5x4.2x2.0 6 14.2 26
96. Tamil Selvi
17941
50,P4L4 4yrs 6.2x4.2x2.0 16 15.62 24
97. Chitra
14981
48,P4L4 6yrs
DM
6.1x3.2x2.1 8 32.2 21
98. Visalatchi
17894
50,P2L2 4yrs
DM
5.4x4.2x2.6 16 7.9 23
99. Meenakshi
17149
47,P3L3 2yrs 5.0x3.4x2.6 8 8.6 27
100. Sivakami
Mariappan
18941
48,P6L6 2 yrs
DM
8.4x6.2x2.4 8 11.5 21
101. B. Eashwari
67238 60 P6L6
1yrs
HT
4.3x2.7x1.2 1.2 10.6 30
102. R. Shanthi
67250 50 P3L3
1yrs 5x2.2x1.4 6 14.6 28
103. S. Kumari
67252 65 P4L4
8yrs 5x3.8x2.2 14 34.2 22
104. M. Anjalai
67341 70 P4L4
3yrs
DM
4.1x2.7x1.1 3 16 23
105. A. Ganga
67341 67 P2L2
1yrs
DM
3.6x2.9x1.4 4 8.8 25
106. R. Pappa
67359 73 P4L4
2yrs 3.9x1.8x1.6 5 11.4 31
107. K. Sumathi
67378 60 P4L4
2yrs
HT
4.0x2.0x1.4 4 17.8 26
108. M.Khursheedbegum
67508   55 P6L6
11/2yrs
DM
4.4x2.0x1.1 3 32.6 24
109. Threseammal
67489 60 P2L2
3yrs
DM
3.9x2.0x1.6 5 16.6 26
110. S.Mallika
67488 59 P3L3
4yrs
DM
4.8x2.3x1.1 5 7.8 21
111. P.Dhanam
67520 54 P4L4
2yrs back
HT
6.3x5.3x4.2 16 14.4 24
112. R.Kasturi
67623
50,P8L8 2yrs 5x3.2x2.4 10 12.2 27
113. M.Deivanai
67563
50,P7L7 3yrs
HT
6.4x3.2x3.4 6 12.6 25
114. K.Nagamma
67856
44,P2L2 2yrs
DM
5.2x2.3x1.1 4 14.4 22
115. Sheela
67756
54,P5L5 4yrs 4.8x2.8x1.2 5 16.2 28
116. Rajalshmi
67823
42,P3L3 3yrs 4.6x2.1x1.3 5 17 24
117. S.Govindammal
67420 60 P6L6
3yrs
DM
4.0x2.5x1.4 5 12.6 21
118. M.Delli
67752 50 P3L3
4yrs
HT
6.4x2.3x1.1 10 15.6 23
119. Bangajammal
67632 65 P4L4
4yrs 5.4x3.0x2.9 8 18.9 23
120. Kamatchi
5623 70 P4L4
4yrs
DM
4.1x1.1x2.1 5 12.6 21
121. Lakshmi
4569 67 P2L2
2yrs
HT
4.6x2.1x1.9 8 12.4 32
122. L.Palaniyammal
56321 73 P4L4
10yrs 3.6x2.5x1.6 4 17.2 26
123. Sridevi.R
56987
4yrs 5.2x3.0x2.6 8 18 24
124. Saratha
86523 60 P6L6
9yrs
HT
4.6x2.1x1.1 4 32.2 20
125. P.Mary
59624 50 P3L3
2yrs 4.8x3.1x2.6 11 14.32 28
126. M.Maheshwari
45632
65 P4L4
2yrs
DM
4.3x2.7x1.2 1.2 16.2 27
127. P. Rajkumar
45328 70 P4L4
12yrs back
HT
5x2.2x1.4 6 15.25 31
128. S. Chandra
8562
67 P2L2 11yrs 5x3.8x2.2 14 16 25
129. R. Rajathi
95632 73 P4L4
8yrs 4.1x2.7x1.1 3 12.5 22
130. K. Shantha
84512 60 P4L4
7yrs
DM
3.6x2.9x1.4 4 11.6 24
131. Bhanumathy
11990
48,P2L2 8yrs 3.9x1.8x1.6 5 14.2 27
132. Ranikutty
11501
48,P3L3 2yrs 4.0x2.0x1.4 4 27.8 26
133. Kamala
6869
60,Nullipara 30yrs
DM
4.4x2.0x1.1 3 10.25 21
134. Muniamma
9497
54,P2L2 4yrs
HT
3.9x2.0x1.6 5 12.5 25
135. Rakayee
21865
49,P3L3 6yrs 4.8x2.3x1.1 5 28.6 30
136. Shanthi
23793
52,P4L3 2yrs 6.3x5.3x4.2 16 11.26 25
137. Kathammal
13897
50,P6L6 2yrs 5x3.2x2.4 10 14.4 26
138. Selvi
14901
49,P5L4 6yrs
HT
6.4x3.2x3.4 6 14.8 28
139. Sundari
13741
50,P2L1 6yrs 5.2x2.3x1.1 4 30.24 23
140. Karupayee
8498
49,P4L2 10yrs
DM
4.8x2.8x1.2 5 30.1 20
141. Senthil
9430
49,P3L2 2yrs
DM
4.6x2.1x1.3 5 15 24
142. Sivapayee
16981
48,P2L3 2yrs 4.0x2.5x1.4 5 12.2 26
143. Kalairasi
17914
49,P3L1 1yr back
DM
6.4x2.3x1.1 10 38.4 30
144. Laxmi
Elumalai
7937
50,P6L6 6yrs
DM
5.4x3.0x2.9 8 30.4 22
145. Bhanumathy
11990
48,P2L2 4yrs 4.1x1.1x2.1 5 10.9 26
146
.
Kanchana
6990
48,P3L3 6yrs 4.6x2.1x1.9 8 10.6 24
147 Kamala
6779
52, P4L3 4yrs
DM
4.2x1.2x2.0 4 31.6 25
148. Vellammal
7938
75,P3L3 2yrs 4.3x2.7x1.2 1.2 9.6 23
149. Alamelu
11458
54,P2L2 2yrs 5x2.2x1.4 6 9.1 27
150. Rathinam
11463
60,P4L4 2 yrs
DM
5x3.8x2.2 14 32.4 21
